# EDGAR Filing Document

**Accession Number:** 0001626971
**File Stem:** 0001171843-25-003881
**Filing Date:** 2025-6
**Character Count:** 6298
**Document Hash:** ec14c303862cb0098725cd42acadcbbd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-003881.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001171843-25-003881

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250612

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250613

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Corvus Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001626971
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464670809
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37719
- **FILM NUMBER:** 251046335

**BUSINESS ADDRESS:**
- **STREET 1:** 863 MITTEN ROAD
- **STREET 2:** SUITE 102
- **CITY:** BURLINGAME
- **STATE:** CA
- **ZIP:** 94010
- **BUSINESS PHONE:** (650) 900-4520

**MAIL ADDRESS:**
- **STREET 1:** 863 MITTEN ROAD
- **STREET 2:** SUITE 102
- **CITY:** BURLINGAME
- **STATE:** CA
- **ZIP:** 94010

?xml version='1.0' encoding='ASCII'?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the** 

**Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): June 12, 2025** 

## CORVUS PHARMACEUTICALS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37719** | **46-4670809** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification Number)** |

---

---

| | |
|:---|:---|
| **901 Gateway Boulevard, Third Floor**<br> **South San Francisco, CA** | **94080** |
| (Address of principal executive offices) | (Zip code) |

---

**Registrant's telephone number, including area code: (650) 900-4520**

Former name or former address, if changed since last report: Not applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common Stock, Par Value $0.0001 per share | CRVS | Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 12, 2025, Corvus Pharmaceuticals, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). Only stockholders of record at the close of business on April 17, 2025, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 68,169,461 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 53,395,500 shares of the Company's common stock were voted in person or by proxy for the three proposals set forth below, each of which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 25, 2025.

The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

***Proposal No. 1 — Election of Directors***

The Company's stockholders elected the Class III director nominees below to the Company's Board of Directors to hold office until the 2028 Annual Meeting of Stockholders or until his respective successor is elected and qualified or appointed, or the earlier of his death, resignation or removal.

---

| | | | |
|:---|:---|:---|:---|
| **Class III Director Nominees** | **Votes For** | **Votes Withheld** | **Broker Non**-**Votes** |
| Ian T. Clark | 28853180 | 10420373 | 14121947 |
| Peter A. Thompson, M.D. | 38832016 | 441537 | 14121947 |

---

 ****

***Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm***

The Company's stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstain** |
| 53137052 | 117988 | 140460 |

---

 ****

***Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers***

On a non-binding advisory basis, the Company's stockholders approved the compensation of the Company's named executive officers.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstain** | **Broker Non-Votes** |
| 37113137 | &nbsp;&nbsp;&nbsp;&nbsp;2,096,601 | 63815 | 14121947 |

---

 **

 ****

 

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CORVUS PHARMACEUTICALS, INC.** | **CORVUS PHARMACEUTICALS, INC.** |
| Date: June 13, 2025 | By: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; /s/ Leiv Lea <br>|
|  |  | Leiv Lea |
|  |  | Chief Financial Officer |

---